Other
LAI
0
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
LAI is an early-stage landscape with 0 programs across 3 companies. The most active players are Sun Pharmaceutical Industries, Inc., LEO Pharma, Bayer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
10
clinical trials
Completed7 · 70%
Unknown status2 · 20%
Withdrawn1 · 10%
Clinical Trials
Trial Activity
10 trials
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
Completed·—·Phase 3·NCT00445107·198 enrolled
First Step With Singulair® Therapy (0476-323)
Completed·—·Phase 4·NCT00545324·399 enrolled
Xolair Interventional Study in ASD Patients With Comorbid Atopy
Withdrawn·—·Phase 1·NCT04535817
LAIV (Flumist®) Administration in CF Patients
Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT01885169·170 enrolled
The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils
Unknown status·—·Phase 4·NCT00673218·25 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)